Boosting T cell costimulation in cancer: The possibilities seem endless

International Reviews of Immunology

Volumn 22, Issue 2, 2003, Pages 173-194

  Evans, Dean E ^a   Weinberg, Andrew D ^a,b  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

Cancer; Costimulation; T cell activation

Indexed keywords

B7 ANTIGEN; TUMOR NECROSIS FACTOR;

ANTIGEN PRESENTING CELL; CANCER; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSTIMULATION; MOLECULAR INTERACTION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES;

EID: 0038038022     PISSN: 08830185     EISSN: None     Source Type: Journal    
DOI: 10.1080/08830180305219     Document Type: Review

References (118)

1. P.A. Cohen, L. Peng, G.E. Plautz, J.A. Kim, D.E. Weng, and S. Shu, CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit. Rev. Immunol, 20: 17-56, 2000.
2. H.M. Hu, H. Winter, W.J. Urba, and B.A. Fox, Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy. J. Immunol., 165: 4246-4253, 2000.
3. F.H. Durie, T.M. Foy, S.R. Masters, J.D. Laman, and R.J. Noelle, The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunology Today, 15: 406-411, 1994.
4. T.M. Foy, A. Aruffo, J. Bajorath, J.E. Buhlmann, and R.J. Noelle, Immune regulation by CD40 and its ligand GP39. Ann. Rev. Immunol., 14: 591-617, 1996.
5. P.A. Bretscher, and M. A Cohn, Theory of self and non self discrimination. Science, 169: 1042-1049, 1970.
6. M.K. Jenkins, and R.H. Schwartz, Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med., 165: 302-319, 1987.
7. M.K. Jenkins, C.A. Chen, G. Jung, D.L. Mueller, and R.H. Schwartz, Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J. Immunol., 144: 16-22, 1990.
8. M.K. Jenkins, P.S. Taylor, S.D. Norton, and K.B. Urdahl, CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J. Immunol., 147: 2461-2466, 1991.
9. S.D. Norton, L. Zuckerman, K.B. Urdahl, R. Shefner, J. Miller, and M.K Jenkins, The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells. J. Immunol., 149: 1556-1561, 1992.
10. K.B. Urdahl, M.K. Jenkins, and S.D. Norton, Accessory cell-derived costimulatory signals regulate T cell proliferation. Ann. NY Acad. Sci., 636: 33-42, 1991.
11. A.S. Freedman, G. Freeman, J.C. Horowitz, J. Daley, and L.M. Nadler, B7, a B ell-restricted antigen that identifies preactivated B cells. J. Immunol., 139: 3260-3267, 1987.
12. G.J. Freeman, F. Borriello, R.J. Hodes, H. Reiser, J.G. Gribben, J.W. Ng, J. Kim, J.M. Goldberg, K. Hathcock, G. Laszlo, et al. Murine B7-2, an alternative CTLA-4 counter-receptor that costimulates T cell proliferation and interleukin-2 production. J. Exp. Med., 178: 2185-2192, 1993a.
13. G.J. Freeman, J.G. Gribben, V.A. Boussiotis, J.W. Ng, V.A.J. Restivo, L.A. Lombard, G.S. Gray, and L.M. Nadler, Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation. Science, 262: 909-911, 1993b.
14. P.S. Linsley, J.L. Greene, W. Brady, J. Bajorath, J.A. Ledbetter, and R. Peach, Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity, 1: 793-801, 1995.
15. L.L. Lanier, S. O'Fallon, C. Somoza, J.H. Phillips, P.S. Linsley, K. Okumura, D. Ito, and M Azuma, CD80 (B7-1) and CD86 (B7-2) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol., 154: 97-105, 1995.
16. D.E. Evans, M.W. Munks, J.M. Purkerson, and D.C. Parker, Resting B lymphocytes as APC for naive T lymphocytes: Dependence on CD40 ligand/CD40. J. Immunol., 164: 688-697, 2000.
17. K.S. Hathcock, G. Laszlo, C. Pucillo, P. Linsley, and R.J. Hodes, Comparative analysis of B7-1 and B7-2 costimulatory ligands: Expression and function. J. Exp. Med., 180: 631-640, 1994.
18. M. Roy, A. Aruffo, J.A. Ledbetter, P. Linsley, M. Kehry, and R.J. Noelle, Studies on the interdependence of gp39 and B7 expression and function during antigenspecific immune responses. Eur. J. Immunol., 25: 596-603, 1995.
19. C. Dubey, M. Croft, and S.L. Swain, Costimulatory requirements of naive CD4(+) T cells: ICAM-1 or B7-1 can costimulate naive CD4 T cell activation but both are required for optimum response. J. Immunol., 155: 45-57, 1995.
20. J.A. Sogn, Tumor immunology: The glass is half full. Immunity, 9: 757-763, 1998.
21. S. Baskar, S. Ostrand-Rosenberg, N. Nabavi, L.M. Nadler, G.J. Freeman, and L.H. Glimcher, Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA, 90: 5687-5690, 1993.
22. L. Chen, S. Ashe, W.A. Brady, I. Hellstrom, K.E. Hellstrom, J.A. Ledbetter, P. McGowan, and P. S Linsley, Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71: 1093-1102, 1992.
23. L. Chen, P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellstrom, and K. E. Hell trom, Tumor immiinogenicity determines the effect of B7 costimulation on T cell-ediated tumor immunity. J. Exp. Med., 179: 523-532, 1994a.
24. L. Chen, P. McGowan, S. Ashe, J.V. Johnston, I. Hellstrom, and K.E. Hellstrom, B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res., 54: 5420-5423, 1994b.
25. S.E. Townsend, and J.P. Allison, Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science, 259: 368-370, 1993.
26. S.E. Townsend, F.W. Su, J.M. Atherton, and J.P. Allison, Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res., 54: 6477-6483, 1994.
27. U. Matulonis, C. Dosiou, G. Freeman, C. Lamont, P. Mauch, L.M. Nadler, and J.D. Griffin, B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity: Further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol., 156: 1126-1131, 1996.
28. M.J. Bevan, Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med., 143: 1283-1288, 1976a.
29. M.J. Bevan, Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J. Immunol., 117: 2233-2238, 1976b.
30. F.R. Carbone, C. Kurts, S.R. Bennett, J.F. Miller, and W.R. Heath, Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol. Today, 19: 368-373, 1998.
31. A.Y. Huang, P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H Levitsky, Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science, 264: 961-965, 1994.
32. P. Jeannin, T. Renno, L. Goetsch, I. Miconnet, J.P. Aubry, Y. Delneste, N. Herbault, T. Baussant, G. Magistrelli, C Soulas, et al. Omp A targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat. Immunol., 1: 502-509, 2000.
33. K. Runyon, K. Lee, K. Zuberek, M. Collins, J.P. Leonard, and K. Dunussi-Joannopoulos, The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses. Blood, 97: 2420-2426, 2001.
34. K. Sturmhoefel, K. Lee, G.S. Gray, J. Thomas, R. Zollner, M. O'Toole, H. Swiniarski, A. Dorner, and S.F. Wolf, Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant. Cancer Res., 59: 4964-4972, 1999.
35. C.A. Chambers, M.S. Kuhns, J.G. Egen, and J. P Allison, CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Ann. Rev. Immunol., 19: 565-594, 2001.
36. T.L. Walunas, D.J. Lenschow, C.Y. Bakker, P.S. Linsley, G.J. Freeman, J.M. Green, J.M. Thompson, and J. A Bluestone, CTLA-4 can function as a negative regulator of T cell activation. Immunity, 1: 405-413, 1994.
37. M.L. Alegre, P.J. Noel, B.J. Eisfelder, E. Chuang, M.R. Clark, S.L. Reiner, and C.B. Thompson, Regulation of surface and intracellular expression of CTLA-4 on mouse T cells. J. Immunol., 157: 4762-4770, 1996.
38. E.A. Tivol, F. Borriello, A.N. Schweitzer, W.P. Lynch, J.A. Bluestone, and A.H. Sharpe, Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 3: 541-547, 1995.
39. P. Waterhouse, J.M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K.P. Lee, C.B. Thompson, H. Griesser, and T.W. Mak, Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science, 270: 985-988, 1995.
40. M.C. Brunner, C.A. Chambers, F.K. Chan, J. Hanke, A. Winoto, and J.P. Allison, CTLA-4-Mediated inhibition of early events of T cell proliferation, J. Immunol., 162: 5813-5820, 1999.
41. D.R. Leach, M.F. Krummel, and J.P. Allison, Enhancement of antitumor immunity by CTLA-4 blockade. Science, 271: 1734-1736, 1996.
42. P. Shrikant, and M.F. Mescher, Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J. Immunol., 162: 2858-2866, 1999.
43. E.M. Sotomayor, I. Borrello, E. Tubb, J.P. Allison, and H.I. Levitsky, In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc. Natl. Acad. Sci. USA, 96: 11476-11481, 1999.
44. Y.F. Yang, J.P. Zou, J. Mu, R. Wijesuriya, S. Ono, T. Walunas, J. Bluestone, H. Fujiwara, and T. Hamaoka, Enhanced induction of antitumor T cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res., 57: 4036-4041, 1997.
45. A. van Elsas, A.A. Hurwitz, and J.P. Allison, Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med., 190: 355-366, 1999.
46. A.A. Hurwitz, T.F. Yu, D.R. Leach, and J.P. Allison, CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA, 95: 10067-10071, 1998.
47. M.B. Mokyr, T. Kalinichenko, L. Gorelik, and J.A. Bluestone, Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res., 58: 5301-5304, 1998.
48. S.A. Rosenberg, and D.E. White, Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol., 19: 81-84, 1996.
49. K. Agematsu, T. Kobata, K. Sugita, G.J. Freeman, M.P. Beckmann, S.F. Schlossman, and C. Morimoto, Role of CD27 in T cell immune response. Analysis by recombinant soluble CD27. J. Immunol., 153: 1421-1429, 1994.
50. L.A. Gravestein, J.D. Nieland, A.M. Kruisbeek, and J. Borst, Novel mAbs reveal potent co-stimulatory activity of murine CD27. Int. Immunol., 7: 551-7, 1995.
51. R.Q. Hintzen, S.M. Lens, K. Lammers, H. Kuiper, M.P. Beckmann, and R.A. van Lier, Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J. Immunol., 154: 2612-2623, 1995.
52. T. Kobata, K. Agematsu, J. Kameoka, S.F. Schlossman, and C. Morimoto, CD27 is a signal-transducing molecule involved in CD45RA+ naive T cell costimulation. J. Immunol., 153: 5422-5432, 1994.
53. K. Takeda, H. Oshima, H. Hayakawa, H. Akiba, M. Atsuta, T. Kobata, K. Kobayashi, M. Ito, H. Yagita, and K. Okumura, CD27-mediated activation of murine NK cells. J. Immunol., 164: 1741-1745, 2000.
54. F.C. Yang, K. Agematsu, T. Nakazawa, T. Mori, S. Ito, T. Kobata, C. Morimoto, and A. Komiyama, CD27/CD70 interaction directly induces natural killer cell killing activity. Immunology, 88: 289-293, 1996.
55. R.Q. Hintzen, R. de Jong, S.M. Lens, M. Brouwer, P. Baars, and R.A. van Lier, Regulation of CD27 expression on subsets of mature T-lymphocytes. J. Immunol., 151: 2426-2435, 1993.
56. R.Q. Hintzen, R. de Jong, S.M. Lens, and R.A. van Lier, CD27: Marker and mediator of T cell activation? Immunol. Today, 15: 307-311, 1994a.
57. R.Q. Hintzen, S.M. Lens, M.P. Beckmann, R.G.Goodwin, D. Lynch, and R.A.W. van Lier, Characterization of the human CD27 ligand, a novel member of the TNF gene family. J. Immunol., 152: 1762-1773, 1994b.
58. R.Q. Hintzen, S.M. Lens, G. Koopman, S.T. Pals, H. Spits, and R.A. van Lier, CD70 represents the human ligand for CD27. Int. Immunol., 6: 477-480, 1994c.
59. S.M. Lens, K. Tesselaar, M.H. van Oers, and R.A. van Lier, Control of lymphocyte function through CD27-CD70 interactions. Semin. Immunol., 10: 491-499, 1998.
60. H. Oshima, H. Nakano, C. Nohara, T. Kobata, A. Nakajima, N.A. Jenkins, D.J. Gilbert, N.G. Copeland, T. Muto, H. Yagita, and K. Okumura, Characterization of murine CD70 by molecular cloning and mAb. Int. Immunol., 10: 517-526, 1998.
61. J. Hendriks, L.A. Gravestein, K. Tesselaar, R.A. van Lier, T.N. Schumacher, and J. Borst, CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol., 1: 433-440, 2000.
62. J.M. Kelly, P.K. Darcy, J.L. Markby, D.I. Godfrey, K. Takeda, H. Yagita, and M.J. Smyth, Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol., 3: 83-90, 2002.
63. M.G. Lorenz, J.A. Kantor, J.A. Schlom, and J.W. Hodge, Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 [CD27L]. Hum. Gene Ther., 10: 1095-1103, 1999.
64. M.M. Swallow, J.J. Wallin, and W.C. Sha, B-7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNF-α. Immunity., 11: 423-432, 1999.
65. S.K. Yoshinaga, J.S. Whoriskey, S.D. Khare, U. Sarmiento, J. Guo, T. Horan, G. Shih, M. Zhang, M.A. Coccia, T. Kohno, et al. T cell co-stimulation through B7RP-1 and ICOS. Nature, 402: 827-832, 1999.
66. A. Hutloff, A.M. Dittrich, K.C. Beier, B. Eljaschewitsch, R. Kraft, I. Anagnostopoulos, and R.A. Kroczek, ICOS is an inducible T cell co-stimulator structurally and functionally related to CD28. Nature, 397: 263-266, 1999.
67. A.J. Coyle, S. Lehar, C. Lloyd, J. Tian, T. Delaney, S. Manning, T. Nguyen, T. Burwell, H. Schneider, J.A. Gonzalo, et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity, 13: 95-105, 2000.
68. A.J. McAdam, T.T. Chang, A.E. Lumelsky, E.A. Greenfield, V.A. Boussiotis, J.S. Duke-Cohan, T. Chernova, N. Malenkovich, C. Jabs, V.K. Kuchroo, et al. Mouse inducible costimulatory molecule [ICOS] expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J. Immunol., 165: 5035-5040, 2000.
69. C. Dong, A.E. Juedes, U.A. Temann, S. Shresta, J.P. Allison, N.H. Ruddle, and R.A. Flavell, ICOS co-stimulatory receptor is essential for T cell activation and function. Nature, 409: 97-101,2001.
70. A.J. McAdam, R.J. Greenwald, M.A. Levin, T. Chernova, N. Malenkovich, V. Ling, G.J. Freeman, and A.H. Sharpe, ICOS is critical for CD40-mediated antibody class switching. Nature, 409: 102-105, 2001.
71. A. Tafuri, A. Shahinian, F. Bladt, S.K. Yoshinaga, M. Jordana, A. Wakeham, L.M. Boucher, D. Bouchard, V.S. Chan, G. Duncan, et al. ICOS is essential for effective T-helper-cell responses. Nature, 409: 105-109, 2001.
72. J.P. Allison, A.A. Hurwitz, and D.R. Leach, Manipulation of costimulatory signals to enhance antitumor T cell responses. Curr. Opin. Immunol., 7: 682-686, 1995.
73. J.J. Wallin, L. Liang, A. Bakardjiev, and W.C. Sha, Enhancement of CD8(+) T cell responses by icos/b7h costimulation. J. Immunol., 167: 132-139, 2001.
74. X. Liu, X.F. Bai, J. Wen, J.X. Gao, J. Liu, P. Lu, Y. Wang, P. Zheng, and Y Liu, B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T Lymphocytes In Vivo. J. Exp. Med., 194: 1339-1348, 2001.
75. M.R. Alderson, R.J. Armitage, T.W. Tough, L. Strockbine, W.C. Fanslow, and M.K. Spriggs, CD40 expression by human monocytes: Regulation by cytokines and activation of monocytes by the ligand for CD40. J. Exp. Med., 178: 669-674, 1993.
76. M.R. Alderson, C.A. Smith, T.W. Tough, T. Davis-Smith, R.J. Armitage, B. Falk, E. Roux, E. Baker, G.R. Sutherland, and W.S. Din, Molecular and biological characterization of human 4-1BB and its ligand. Eur. J. Immunol., 24: 2219-2227, 1994.
77. R.G. Goodwin, M.R. Alderson, C.A. Smith, R.J. Armitage, T. Vandenbos, R. Jerzy, T.W. Tough, M.A. Schoenborn, T. Davis-Smith, K. Hennen, et al. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell, 73: 447-456, 1993.
78. C. Takahashi, R.S. Mittler, and A.T. Vella, Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J. Immunol., 162: 5037-5040, 1999.
79. M.A. DeBenedette, N.R. Chu, K.E. Pollok, J. Hurtado, W.F. Wade, B.S. Kwon, and T.H. Watts, Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M 12 B lymphomas by cAMP. J. Exp. Med., 181: 985-992, 1995.
80. J.C. Hurtado, S.H. Kim, K.E. Pollok, Z.H. Lee, and B.S. Kwon, Potential role of 4-BB in T cell activation: Comparison with the costimulatory molecule CD28. J. Immunol., 155: 3360-3367, 1995.
81. H.R. Salih, S.G. Kosowski, V.F. Haluska, G.C. Starling, D.T. Loo, F. Lee, A.A. Aruffo, P.A. Trail, and P.A. Kiener, Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells. J. Immunol., 165: 2903-2910, 2000.
82. I. Melero, N. Bach, N. Hellstrom, A. Aruffo, R.S. Mittler, and L. Chen, Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: Synergy with the CD28 co-stimulatory pathway. Eur. J. Immunol., 28: 1116-1121, 1998.
83. I. Melero, W.W. Shuford, S.A. Newby, A. Aruffo, J.A. Ledbetter, K.E. Hellstrom, R.S. Mittler, and L. Chen, Monoclonal antibodies against the 4-1BB T cell activation molecule eradicate established tumors. Nat. Med., 3: 682-685, 1997.
84. B.A. Guinn, M.A. DeBenedette, T.H. Watts, and N.L. Berinstein, 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J. Immunol., 162: 5003-5010, 1999.
85. D.M. Calderhead, J.E. Buhlmann, A.J. van den Eertwegh, E. Claassen, R.J. Noelle, and H.P. Fell, Cloning of mouse OX40: A T cell activation marker that may mediate T-B cell interactions. J. Immunol., 151: 5261-5271, 1993.
86. H. Drkop, U. Latza, M. Hummel, F. Eitelbach, B. Seed, and H. Stein, Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell, 68: 421-427, 1992.
87. S. Mallett, S. Fossum, and A.N. Barclay, Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes: A molecule related to nerve growth factor receptor. EMBO J., 9: 1063-1068, 1990.
88. H. Akiba, M. Atsuta, H. Yagita, and K. Okumura, Identification of rat OX40 ligand by molecular cloning. Biochem. Biophy. Res. Commun., 251: 131-136, 1998.
89. P.R. Baum, R.B. Gayle, 3rd, F. Ramsdell, S. Srinivasan, R.A. Sorensen, M.L. Watson, M.F. Seldin, E. Baker, G.R. Sutherland, K.N. Clifford, and et al. Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J., 13: 3992-4001, 1994.
90. W.R. Godfrey, F.F. Fagnoni, M.A. Harara, D. Buck, and E.G. Engleman, Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J. Exp. Med., 180: 757-762, 1994.
91. I. Gramaglia, A. Jember, S.D. Pippig, A.D. Weinberg, N. Killeen, and M. Croft, The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J. Immunol., 165: 3043-3050, 2000.
92. I. Gramaglia, A.D. Weinberg, M. Lemon, and M. Croft, OX-40 ligand: A potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol., 161: 6510-6517, 1998.
93. J.R. Maxwell, A. Weinberg, R.A. Prell, and A.T. Vella, Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J. Immunol., 164: 107-112, 2000.
94. + T cell mobilization/memory development and humoral immunity: Comparison of OX-40 with CTLA-4. J. Immunol., 167: 6804-6811, 2001.
95. A. Imura, T. Hori, K. Imada, T. Ishikawa, Y. Tanaka, M. Maeda, S. Imamura, and T. Uchiyama, The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J. Exp. Med., 183: 2185-2195, 1996.
96. A. Imura, T. Hori, K. Imada, S. Kawamata, Y. Tanaka, S. Imamura, and T. Uchiyama, OX40 expressed on fresh leukemic cells from adult T cell leukemia patients mediates cell adhesion to vascular endothelial cells: Implication for the possible involvement of OX40 in leukemic cell infiltration. Blood, 89: 2951-2958, 1997.
97. E. Stuber, M. Neurath, D. Calderhead, H.P. Fell, and W. Strober, Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity, 2: 507-521, 1995.
98. A.D. Weinberg, K.W. Wegmann, C. Funatake, and R.H. Whitham, Blocking OX40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J. Immunol., 162: 1818-1826, 1999.
99. Y. Ohshima, Y. Tanaka, H. Tozawa, Y. Takahashi, C. Maliszewski, and G. Delespesse, Expression and function of OX40 ligand on human dendritic cells. J. Immunol., 159: 3838-3848, 1997.
100. E. Stuber, and W. Strober, The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J. Exp. Med., 183: 979-989, 1996.
101. J. Kjaergaard, J. Tanaka, J.A. Kim, K. Rothchild, A. Weinberg, and S. Shu, Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res., 60: 5514-5521, 2000.
102. A. Morris, J.T. Vetto, T. Ramstad, C.J. Funatake, E. Choolun, C. Entwisle, and A.D. Weinberg, Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo. Breast Cancer Res. Treat., 67: 71-80, 2001.
103. A.D. Weinberg, M.M. Rivera, R. Prell, A. Morris, T. Ramstad, J.T. Vetto., W.J. Urba, G. Alvord, C. Bunce, and J. Shields, Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol., 164: 2160-2169, 2000.
104. J.T. Vetto, S. Lum, A. Morris, M. Sicotte, J. Davis, M. Lemon, and A. Weinberg, Presence of the T cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am. J. Surg., 174: 258-265, 1997.
105. T. Ramstad, T. Lawnickix, J. Vetto, and A. Weinberg, Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T cell costimulatory molecule OX-40. Am. J. Surg., 179: 400-406, 2000.
106. P.P. Lee, C. Yee, P.A. Savage, L. Fong, D. Brockstedt, J.S. Weber, D. Johnson, S. Swetter, J. Thompson, P.D. Greenberg, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med., 5: 677-685, 1999.
107. P. Shrikant, A. Khoruts, and M.F. Mescher, CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity, 11: 483-493, 1999.
108. K. Staveley-O'Carroll, E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky, Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA, 95: 1178-1183, 1998.
109. P. Bansal-Pakala, A.G. Jember, and M. Croft, Signaling through OX40 (CD134) breaks peripheral T cell tolerance. Nat. Med., 7: 907-912, 2001.
110. Y. Agata, A. Kawasaki, H. Nishimura, Y. Ishida, T. Tsubata, H. Yagita, and T. Honjo, Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes, Int. Immunol., 8: 765-772, 1996.
111. G.J. Freeman, A.J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L.J. Fitz, N. Malenkovich, T. Okazaki, M.C. Byrne, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med., 192: 1027-1034, 2000.
112. H. Dong, G. Zhu, K. Tamada, and L. Chen, B7-H1, a third member of the B7 family, co-stimulates T cell proliferation and interleukin-10 secretion. Nat. Med., 5: 1365-1369, 1999.
113. Y. Latchman, C.R. Wood, T. Chernova, D. Chaudhary, M. Borde, I. Chernova, Y. Iwai, A.J. Long, J.A. Brown, R. Nunes, et al. PD-L2 is a second ligand for PD-I and inhibits T cell activation. Nat. Immunol., 2: 261-268, 2001.
114. H. Nishimura, M. Nose, H. Hiai, N. Minato, and T. Honjo, Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motifcarrying immunoreceptor. Immunity, 11: 141-151, 1999.
115. H. Nishimura, T. Okazaki, Y. Tanaka, K. Nakatani, M. Hara, A. Matsumori, S. Sasayama, A. Mizoguchi, H. Hiai, N. Minato, and T. Honjo, Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science, 291: 319-322, 2001.
116. H. Nishimura, N. Minato, T. Nakano, and T. Honjo, Immunological studies on PD-1 deficient mice: Implication of PD-1 as a negative regulator for B cell responses. Int. Immunol., 10: 1563-1572, 1998.
117. A.I. Chapoval, J. Ni, J.S. Lau, R.A. Wilcox, D.B. Flies, D. Liu, H. Dong, G.L. Sica, G.L. Zhux, K. Tamada, and L. Chen, B7-H3: A costimulatory molecule for T cell activation and IFN-gamma production. Nat. Immunol., 2: 269-274, 2001.
118. S.Y. Tseng, M. Otsuji, K. Gorski, X. Huang, J.E. Slansky, S.I. Pai, A. Shalabi, T. Shin, D.M. Pardoll, and H. Tsuchiya, B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med., 193: 839-846, 2001.